- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02439437
Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-Mastectomy Pain
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Persistent pain following breast cancer surgery is increasingly being recognized as an important clinical and public health issue due to the large numbers of women affected, the negative impact that persistent pain has on emotional and physical functioning, and its financial cost. Most of the 230,000 women that are expected to be newly diagnosed with breast cancer in the U.S. this year will undergo surgical treatment. Surgical removal of the affected breast (mastectomy) or excision of the tumor (lumpectomy) followed by radiation markedly reduces the risk of disease progression and mortality. However, women undergoing even the more limited lumpectomy are at substantial risk for persistent pain. Estimates of pain's prevalence range from 25-60% across multiple studies, with rates differing based on the stringency of the definition of persistent pain. In one recent study, 32.5% of the women who had undergone breast cancer surgery reported clinically significant persistent pain, defined as a 3/10-pain severity rating for the breast, axilla, side, or arm.
Unlike acute post-operative pain, which is considered to be a normal response to surgical trauma, persistent pain has little biological utility and has proven difficult to treat once established. A critical question is whether there are modifiable factors that contribute to the risk of developing persistent pain following breast cancer surgery that could be targeted for early, preventative intervention. To date, attempts to reduce the risk of persistent pain have focused on alterations in medical/surgical procedures; these studies have had mixed results, consistent with mixed findings in the broader literature regarding the status of medical/surgical variables as risk factors for persistent pain. In contrast, there have been multiple studies showing associations between pain catastrophizing, depression, and anxiety and persistent pain. In these studies, pain catastrophizing shows the strongest and most consistent relationship to persistent pain as evidenced in a recent meta-analysis. Consistent with the biopsychosocial theory of pain, there is also evidence from quantitative sensory testing (QST) studies that alterations in central pain modulation pathways contribute to the development of post-surgical persistent pain, including recent studies with breast cancer patients. Since pain catastrophizing has been found to be associated with pernicious alterations in central pain modulation intervening to reduce catastrophizing may be a particularly effective prevention strategy for persistent pain following breast cancer surgery. Pain coping skills training (PCST) interventions based on cognitive-behavioral principles are the only interventions demonstrated to reduce catastrophizing, alter central modulation of pain and reduce chronic pain.
The overarching hypothesis for the proposed pilot study (N=60) is that a targeted PCST protocol specifically designed for women at risk for persistent pain following breast cancer surgery (pain score of 3 or greater [0-10 scale] during the first 9 months post-surgery) will significantly reduce this devastating consequence of treatment compared to usual care with printed education materials.
Aim 1: To use a pilot RCT (N=60) to examine the feasibility, acceptability, and engagement in the targeted PCST protocol. Feasibility will be assessed by examining overall accrual, attrition, and adherence to the study protocol, engagement will be assessed by the use of intervention sessions and questionnaires (number completed), and acceptability will be assessed with a standardized measure of satisfaction.
Aim 2: To obtain an estimate of the effect size of the targeted PCST protocol for persistent post-surgical pain in comparison to the usual care condition. Effect sizes for group differences on pain burden, symptoms of anxiety and depression, breast cancer specific distress, perceived stress, sleep, interference with daily activities, pain catastrophizing, and hypothesized changes in peripheral sensitivity and central inhibition will also be computed.
The proposed study represents the next critical step in research examining persistent pain after surgical treatment for breast cancer. The proposed study will provide the necessary preliminary data for larger studies aimed at testing the targeted PCST intervention. This study will also provide preliminary data for future studies focused on pain sensitivity and central pain modulation in breast cancer survivors
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- prior diagnosis of Stage 0 to Stage III breast cancer
- received first breast surgery of total or partial mastectomy within the previous 9 months
- report average pain >/= 3 during the first 9 months after surgery on the Breast Cancer Pain Questionnaire
- with sufficient ability to communicate in English in order to provide informed consent and complete study procedures and materials.
Exclusion Criteria:
- < 21 years of age
- history of prior breast cancer surgery
- cognitive impairment documented in the medical record
- unable to provide meaningful consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Treatment as usual
|
|
|
Active Comparator: Psychosocial Intervention
Telephone-based psychosocial intervention involving Eight telephone encounters.
Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
|
Telephone-based psychosocial intervention involving Eight telephone encounters.
Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Pain Burden
Time Frame: 0 month, mid intervention(at 6 weeks), post intervention( 3 months) and 6 months
|
The investigators will use BCPQ (Brest Cancer Pain Questionnaire) questionnaire to record breast pain
|
0 month, mid intervention(at 6 weeks), post intervention( 3 months) and 6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Pro00055890
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Psychosocial Intervention
-
University of Southern MississippiMy Brother's KeeperCompletedCardiovascular DiseasesUnited States
-
IVI SevillaIVI MadridCompletedAnxiety Depression | Psychosocial Stressor | Infertility Primary
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Terminated
-
College of Professional and Continuing Education...SuspendedInsomnia | Randomised Controlled TrialHong Kong
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedMalignant Neoplasm | Psychosocial Effects of Cancer and Its TreatmentUnited States
-
University of Lausanne HospitalsCompletedGestational Diabetes MellitusSwitzerland
-
Sykehuset Innlandet HFNorwegian Medical AssociationCompleted
-
Teesside UniversityUniversity of Manchester; Jos University Teaching HospitalNot yet recruitingStress | Anxiety | Trauma | Depression, Anxiety | Child Behaviour | Woman Abuse | Parenting Intervention
-
The Mediterranean Institute for the Advance of...Carlos III Health Institute; Andaluz Health Service; Preventive Services and...Completed
-
University of North Carolina, Chapel HillRoche Pharma AGCompletedHepatitis C | Substance Use Disorders | Mental DisorderUnited States